BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20008224)

  • 1. Independent prognostic factors for AML outcome.
    Grimwade D; Hills RK
    Hematology Am Soc Hematol Educ Program; 2009; ():385-95. PubMed ID: 20008224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
    Mandelli F; Petti MC; Lo Coco F
    Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
    Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
    Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
    Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
    Venditti A; Maurillo L; Buccisano F; Del Poeta G; Mazzone C; Tamburini A; Del Principe MI; Consalvo MI; De Fabritiis P; Cudillo L; Picardi A; Franchi A; Lo-Coco F; Amadori S
    Leukemia; 2003 Nov; 17(11):2178-82. PubMed ID: 14576731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Poeta G; Gattei V; Amadori S; Venditti A
    Haematologica; 2006 Dec; 91(12 Suppl):ELT14; author reply ELT15. PubMed ID: 17194674
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular characteristics therapy in AML.
    Radich GP
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):11-4. PubMed ID: 19645131
    [No Abstract]   [Full Text] [Related]  

  • 11. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
    Shi XL; Tang XW; Wei XA; Zhao BR; Zhou QL; Ye F; Lu YX; Sun XW; Zhu MQ; Shen WH; Qiu HY; Sun AN; Wu DP
    Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2692-6. PubMed ID: 22321979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
    Pérez-García A; Brunet S; Berlanga JJ; Tormo M; Nomdedeu J; Guardia R; Ribera JM; Heras I; Llorente A; Hoyos M; Esteve J; Besalduch J; Bueno J; Sierra J; Gallardo D;
    Leukemia; 2009 Mar; 23(3):486-91. PubMed ID: 19092854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors.
    Oosterveld M; Muus P; Suciu S; Koller C; Verhoef G; Labar B; Wijermans P; Aul C; Fière D; Selleslag D; Willemze R; Gratwohl A; Ferrant A; Mandelli F; Cortes J; de Witte T; Estey E;
    Leukemia; 2002 Sep; 16(9):1615-21. PubMed ID: 12200672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
    Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
    Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.